2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
178
Endocrine
178
Gastrointestinal
21
Thoracic
20
CNS
17
Genitourinary
14
Gynecologic
11
Dermatologic
11
Breast
11
Sarcoma
6
Lymphoid
5
Other hematologic neoplasm
3
NET
3
Plasma cell
2
Other solid neoplasm
2
Myeloid
2
Conditions
Multiple Myeloma
3577
Neoplasms, Plasma Cell
696
Lymphoma
531
Lymphoma, Non-Hodgkin
480
Leukemia, Lymphocytic, Chronic, B-Cell
409
Hodgkin Disease
405
Recurrence
404
Precursor Cell Lymphoblastic Leukemia-Lymphoma
375
Leukemia
373
Leukemia, Myeloid, Acute
363
Myelodysplastic Syndromes
331
Lymphoma, Large B-Cell, Diffuse
290
Lymphoma, Mantle-Cell
288
Lymphoma, Follicular
284
Lymphoma, B-Cell, Marginal Zone
256
Burkitt Lymphoma
249
Immunoglobulin Light-chain Amyloidosis
227
Myeloproliferative Disorders
226
Lymphoma, Large-Cell, Immunoblastic
223
Neoplasms
214
Hematologic Neoplasms
200
Primary Myelofibrosis
186
Leukemia, Myeloid, Chronic-Phase
182
Leukemia, Myeloid, Accelerated Phase
173
Lymphoma, T-Cell, Cutaneous
170
Waldenstrom Macroglobulinemia
164
Blast Crisis
162
Leukemia, Myelomonocytic, Chronic
158
Mycosis Fungoides
147
Sezary Syndrome
146
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
Plasma cell
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled